{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T17:57:36Z","timestamp":1767117456360,"version":"build-2065373602"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"am","delay-in-days":235,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jbspin.2022.105380","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T11:41:45Z","timestamp":1651146105000},"page":"105380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study and a meta-analysis"],"prefix":"10.1016","volume":"89","author":[{"given":"Maxime","family":"Auroux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baptiste","family":"Coste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Massy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Durieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrille B.","family":"Confavreux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Lega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Mainbourg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Coury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2022.105380_bib0275","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105380_bib0280","doi-asserted-by":"crossref","first-page":"R171","DOI":"10.1186\/ar4358","article-title":"Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis","volume":"15","author":"Crnkic Kapetanovic","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2022.105380_bib0285","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s13075-015-0863-3","article-title":"Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients","volume":"17","author":"Migita","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2022.105380_bib0290","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/annrheumdis-2018-213222","article-title":"Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105380_bib0295","doi-asserted-by":"crossref","first-page":"R209","DOI":"10.1186\/ar3542","article-title":"Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor","volume":"13","author":"Kobie","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2022.105380_bib0300","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/annrheumdis-2021-221244","article-title":"Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"80","author":"Friedman","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105380_bib0305","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2022.105380_bib0310","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jbspin.2022.105380_bib0315","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2022.105380_bib0320","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2022.105380_bib0325","doi-asserted-by":"crossref","first-page":"105334","DOI":"10.1016\/j.jbspin.2021.105334","article-title":"Polymyalgia rheumatica following COVID-19 vaccination: a case-series of ten patients","volume":"89","author":"Ottaviani","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2022.105380_bib0330","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jbspin.2020.05.003","article-title":"Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: a population-based study in the first two months of COVID-19 outbreak in Italy","volume":"87","author":"Quartuccio","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2022.105380_bib0335","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2665-9913(21)00059-X","article-title":"COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study","volume":"3","author":"Avouac","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105380_bib0340","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.41619","article-title":"COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US multicenter, comparative cohort study","volume":"73","author":"D'Silva","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105380_bib0345","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/annrheumdis-2020-218310","article-title":"FAI2R\/SFR\/SNFMI\/SOFREMIP\/CRI\/IMIDIATE consortium and Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients","volume":"80","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105380_bib0350","doi-asserted-by":"crossref","first-page":"e001464","DOI":"10.1136\/rmdopen-2020-001464","article-title":"Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"7","author":"Hasseli","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2022.105380_bib0355","article-title":"Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab","author":"Schulze-Koops","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105380_bib0360","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(21)00151-X","article-title":"Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study","author":"Shin","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105380_bib0365","article-title":"American College of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 2","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105380_bib0370","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.11299","article-title":"Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis","author":"Ammitzb\u00f8ll","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105380_bib0375","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220503","article-title":"Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2","author":"Braun-Moscovici","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105380_bib0380","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105380_bib0385","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220272","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort","author":"Geisen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105380_bib0390","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","author":"Haberman","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105380_bib0395","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2021.06.016","article-title":"Humoral immune response to messenger RNA COVID-19 vaccines among patients with inflammatory bowel disease","author":"Kappelman","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jbspin.2022.105380_bib0400","article-title":"Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD","author":"Kennedy","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jbspin.2022.105380_bib0405","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01469-5","article-title":"Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial","author":"Medeiros-Ribeiro","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jbspin.2022.105380_bib0410","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220781","article-title":"SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity","author":"Mrak","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105380_bib0415","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220656","article-title":"High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases","author":"Ruddy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105380_bib0420","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(21)00186-7","article-title":"Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis","author":"Rubbert-Roth","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105380_bib0425","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220461","article-title":"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases","author":"Simon","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105380_bib0430","article-title":"Brief Report: Humoral and cellular immune responses to SARS-CoV-2 infection and vaccination in B cell depleted autoimmune patients","author":"Simon","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105380_bib0435","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220604","article-title":"Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases","author":"Spiera","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105380_bib0440","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220736","article-title":"Correspondence on \u201cImmunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.\u201d","author":"Veenstra","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105380_bib0445","article-title":"Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies","author":"Boekel","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105380_bib0450","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-221145","article-title":"Antibody response to the Janssen\/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases","author":"Chiang","year":"2021","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.jbspin.2022.105380_bib0455","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(21)00251-4","article-title":"Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study","author":"Moor","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105380_bib0460","doi-asserted-by":"crossref","first-page":"740249","DOI":"10.3389\/fimmu.2021.740249","article-title":"Immunosuppressivetherapies differently modulate humoral- and T-cell-specific responses to COVID-19 mRNA vaccine in rheumatoid arthritis patients","volume":"12","author":"Picchianti-Diamanti","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jbspin.2022.105380_bib0465","article-title":"inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry","author":"Seror","year":"2021","journal-title":"The Lancet Rheumatology"},{"key":"10.1016\/j.jbspin.2022.105380_bib0470","doi-asserted-by":"crossref","first-page":"108095","DOI":"10.1016\/j.intimp.2021.108095","article-title":"The WHO International Standard for COVID-19 serological tests: towards harmonization of anti-spike assays","volume":"100","author":"Infantino","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jbspin.2022.105380_bib0475","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2022.105380_bib0480","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jbspin.2022.105380_bib0485","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2022.105380_bib0490","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1136\/annrheumdis-2021-220957","article-title":"Correspondence on \u201cSARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response\u201d by Bonelli et al","volume":"80","author":"Chung","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105380_bib0495","doi-asserted-by":"crossref","first-page":"105258","DOI":"10.1016\/j.jbspin.2021.105258","article-title":"SARS CoV-2 vaccine AND rituximab, timing might be a key for a better vaccine response","volume":"88","author":"Verhoeven","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2022.105380_bib0500","unstructured":"Stefanski AL, Rincon-Arevalo H, Schrezenmeier E, Karberg K, Szelinski F, Ritter J, et al. B cell numbers predict humoral and cellular response upon SARS-CoV-2 vaccination among patients treated with rituximab. Arthritis & Rheumatology 10.1002\/art.42060"},{"key":"10.1016\/j.jbspin.2022.105380_bib0505","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2022.105380_bib0510","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(21)00212-5","article-title":"The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study","author":"Mahil","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105380_bib0515","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220408","article-title":"SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response","author":"Bonelli","year":"2021","journal-title":"Ann Rheumat Dis"},{"key":"10.1016\/j.jbspin.2022.105380_bib0520","article-title":"Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab","author":"Felten","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105380_bib0525","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220461","article-title":"Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease","author":"Simon","year":"2021","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.jbspin.2022.105380_bib0530","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2022.105380_bib0535","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","article-title":"Truedsson L, J\u00f6nsson G, Geborek P. Influence of methotrexate. TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis","volume":"45","author":"Kapetanovic","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2022.105380_bib0540","article-title":"Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis","author":"Sakuraba","year":"2021","journal-title":"Gastroenterology"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X22000392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X22000392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:29:13Z","timestamp":1761150553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X22000392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1297319X22000392"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2022.105380","relation":{},"ISSN":["1297-319X"],"issn-type":[{"type":"print","value":"1297-319X"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study and a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2022.105380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105380"}}